Pacira BioSciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $726.4 | $701.0 | $675.0 | $666.8 | $541.5 |
| Operating income | $19.2 | -$73.4 | $87.7 | $60.0 | $89.9 |
| Net income | $7.0 | -$99.6 | $42.0 | $15.9 | $42.0 |
| Cash Flow Statement | |||||
| Free cash flow | $136.7 | $178.8 | $139.5 | $115.2 | $79.9 |
| Share repurchases | $148.3 | $25.0 | $0.0 | $0.0 | — |
Shares outstanding 39.9M · Free float 62.3%
Annual filing data through FY ended December 31, 2025; float as of September 28, 2026.
Coverage
October 11, 2026
Weekly Deals
Micro-Cap Deals Roundup for Week of Oct. 5, 2026
October 8, 2026
Deals
Viatris to Buy Pacira BioSciences in $1.65 Billion Cash Deal
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
June 30, 2026
Deals
Pacira BioSciences to Acquire iovera° in Up to $140 Million Asset-Purchase Deal